ReferencesPackage Insert: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed6657ca-ab68-477a-9968-e12dc928b540
1. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007 Jun;119(6):1497-1503.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17418383
2. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin- receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-541. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20818888
3. Deeks ED. Icatibant. Drugs. 2010;70(1):73-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20030426
4. Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc. 2014 Sep-Oct;35(5):377-81.
http://www.ncbi.nlm.nih.gov/pubmed/25198193
5. Egan M, Wang J. Icatibant Use in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):824-5. http://www.ncbi.nlm.nih.gov/pubmed/26613106
6. Icatibant for Patients with Type III Hereditary Angioedema: A Review of Clinical Effectiveness and Harms [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb. http://www.ncbi.nlm.nih.gov/pubmed/25654149
7. Vaheri A, Strandin T, Jääskeläinen AJ, Vapalahti O, Jarva H et al. Pathophysiology of a severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Antiviral Res. 2014 Nov;111:23-5.
http://www.ncbi.nlm.nih.gov/pubmed/25194993
8. Medjadba W, Martin-Eauclaire MF, Laraba-Djebari F. Involvement of Kallikrein-Kinin System on Cardiopulmonary Alterations and Inflammatory Response Induced by Purified Aah I Toxin from Scorpion Venom. Inflammation. 2015 Sep 11.
http://www.ncbi.nlm.nih.gov/pubmed/26361946
9. Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J et al. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3. Int Arch Allergy Immunol. 2015;168(1):44-55.
http://www.ncbi.nlm.nih.gov/pubmed/26556097
10. J Allergy Clin Immunol. 2016 Nov 29. pii: S0091-6749(16)31376-8. doi: 10.1016/j.jaci.2016.09.051. [Epub ahead of print] Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. Straka BT1, Ramirez CE1, Byrd JB1, Stone E1, Woodard-Grice A1, Nian H2, Yu C2, Banerji A3, Brown NJ4.
11. Clin Exp Immunol. 2016 Dec 9. doi: 10.1111/cei.12910. [Epub ahead of print] Comparing acquired angioedema with hereditary angioedema (type I/II): Findings from the Icatibant Outcome Survey. Longhurst HJ1, Zanichelli A2, Caballero T3, Bouillet L4, Aberer W5, Maurer M6, Fain O7, Fabien V8, Andresen I8; for the IOS Study Group.
12. Immunol Allergy Clin North Am. 2017 Feb;37(1):183-200. doi: 10.1016/j.iac.2016.08.011. The Angiotensin-Converting-Enzyme-Induced Angioedema. Bas M1.
13. Ann Pharmacother. 2016 Jan;50(1):47-59. doi: 10.1177/1060028015607037. Epub 2015 Sep 28. Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema. Culley CM1, DiBridge JN2, Wilson GL Jr3.